ARCUTIS ANNOUNCES HEALTH CANADA APPROVAL OF ZORYVE® (ROFLUMILAST) FOAM 0.3% TO TREAT SEBORRHEIC DERMATITIS IN INDIVIDUALS 9 YEARS OF AGE AND OLDER

Reuters · 10/18 12:20

Please log in to view news